DIAMOS is a cognitive behavioral therapy for people with diabetes and subclinical depression to stimulate their self-management. In a randomized controlled trial, DIAMOS was shown to be effective as fewer depressive symptoms and diabetes-related distress were observed compared to the control group. The probability of clinical depression was reduced by 37% in the intervention group compared to the control group.
Aim
A health economic evaluation carried out as a cost-effectiveness or cost-utility analysis of the DIAMOS cognitive-behavioral intervention program.
Project Lead and Contact Person
Cooperations
Forschungsinstitut an der Diabetes-Akademie (FIDAM) Bad Mergentheim Klinik für Psychosomatik und Psychotherapie, Universität Gießen
Funding
- Bundesärztekammer
- Bundesministerium für Bildung und Forschung (BMBF)
Methods
Patients with diabetes and subclinical depression were randomly assigned either to a two-week diabetes-specific cognitive-behavioral group therapy comprising 5 group sessions of 90 minutes each (n=104) or a standardized diabetes education program (n=104). The patients were monitored for 12 months. During this period, data on total health care costs, patient costs and societal productivity costs were collected in addition to clinical data. Health-related quality of life (the SF-36 and EQ-5D) was measured before the start of the intervention, immediately after the intervention and 6 and 12 months after the intervention. Quality-adjusted life years (QALYs) and cumulative costs are calculated for both strands of the study. Finally, the incremental cost-utility ratio (ICUR) is calculated as cost per QALY obtained. The cost-effectiveness of diabetes-specific cognitive-behavioral therapy is analyzed from the perspective of the German statutory health insurance and from the societal perspective.
Duration
2009-2020
Ausgewählte Publikationen
Chernyak N, Kulzer B, Hermanns N, Schmitt A, Gahr A, Haak T, Kruse J, Ohmann C, Scheer M, Giani G, Icks A. Study protocol: Within-trial economic evaluation of diabetes-specific cognitive behaviour therapy in patients with type 2 diabetes and subthreshold depression. BMC Public Health 2010 Oct 19; 10: 625